A Study to Determine the Rel Bio of AZD9833 Formulations, Food Effects and the Absolute Bioavailability of AZD9833 Following Co-Administration of an Oral Tablet Formulation With a Radiolabelled Intravenous Microdose of [14C]AZD9833
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Camizestrant (Primary) ; Camizestrant (Primary)
- Indications Breast cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 18 Jan 2021 Status changed from recruiting to completed.
- 27 Nov 2020 Planned End Date changed from 28 Dec 2020 to 15 Dec 2020.
- 27 Nov 2020 Planned primary completion date changed from 28 Dec 2020 to 15 Dec 2020.